| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT02621021 A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor… |
Enrollment reduced: 170 -> 53 participants |
| 2026-05-20 | NCT05989828 A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1… |
date change Primary completion pushed: 2026-12-17 -> 2027-12-31 |
| 2026-05-20 | NCT05989828 A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1… |
date change Completion pushed: 2027-12-17 -> 2028-12-31 |
| 2026-05-20 | NCT07591649 Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-28 | NCT07610538 Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on… | Recruiting | |
| 2026-05-18 | NCT07591649 Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | Phase 1/2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT07288073 | TIL Therapy in cSCC and MCC | Cutaneous Squamous Cell Carcinoma | Recruiting |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Cervical Cancer | Recruiting |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | Melanoma Stage III | Recruiting |
| NCT03412877 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors… | Endocrine Tumors | Recruiting |
| NCT05155033 | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal… | Metastatic Melanoma | Recruiting |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | Advanced Non-Small Cell Lung Cancer | Recruiting |
| NCT02621021 | A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor… | Melanoma | Recruiting |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Metastatic Colorectal Cancer | Recruiting |
| NCT01366092 | Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease | Chronic Graft-versus-host Disease | Active, Not Recruiting |
| NCT00338377 | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization… | Melanoma | Active, Not Recruiting |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer… | Bone Sarcoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04263831 | Low Dose IL-2 for the Treatment of Crohn's Disease | Crohn Disease | Recruiting |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced… | HPV-Associated Cervical Carcinoma | Recruiting |
| NCT06961357 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Melanoma | Recruiting |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric… | Pancreatic Cancer | Recruiting |
| NCT06158828 | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted… | AML, Childhood | Recruiting |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in… | Advanced Solid Tumor | Recruiting |
| NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | Relapsed Adult AML | Recruiting |
| NCT06598371 | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to… | Select Advanced Solid Tumors | Recruiting |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor… | Pancreatic Cancer | Recruiting |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to… | Advanced Solid Tumor | Active, Not Recruiting |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced… | Ovarian Cancer | Not Yet Recruiting |
| NCT01038778 | Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney… | Clear Cell Renal Cell Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT06138587 | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia | Recruiting |